TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) central nervous system (CNS) metastases (mets).
Carey K. Anders(Duke University), Lisa A. Carey(University of North Carolina at Chapel Hill), P. Kelly Marcom(Duke University), Antonio C. Wolff(Johns Hopkins University), Minetta C. Liu(Mayo Clinic), Catherine Van Poznak(University of Michigan), Amal Melhem‐Bertrandt(The University of Texas MD Anderson Cancer Center), Nancy U. Lin(Dana-Farber Cancer Institute), Anna Maria Storniolo(Indiana University Health), Vered Stearns(Johns Hopkins University), Charles M. Perou(University of North Carolina at Chapel Hill), Allison M. Deal(Memorial Sloan Kettering Cancer Center), Eric P. Winer(University of Vermont), Olga Karginova(University of Illinois Chicago), Vandana G. Abramson(Vanderbilt University), J. Keith Smith(Merck & Co., Inc., Rahway, NJ, USA (United States)), John T. Carpenter(University of Louisville Hospital), Michelle Melisko(University of California, San Francisco), Shannon Puhalla(UPMC Hillman Cancer Center), Rita Nanda(University of Chicago)
Cited by 4
Related Papers
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k